Lilly to Present Phase II to Treat Autoimmune Diseases; Celgene's ABRAXANE Demonstrates Significant Improvement Print E-mail
By Staff and Wire Reports   
Friday, 09 November 2012 20:07
Below is a look at some of the headlines for companies that made news in the healthcare sector on November 9, 2012

Eli Lilly and Company (NYSE: LLY)
will present Phase II data in rheumatoid arthritis (RA) for two of its investigational autoimmune medicines at the annual meeting of the American College of Rheumatology (ACR), which takes place Nov. 10-14, 2012, in Washington, D.C.

These compounds include tabalumab, an anti-BAFF monoclonal antibody, and baricitinib, a janus kinase (JAK) inhibitor being developed in partnership with Incyte Corporation.


Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG) announced its phase III study of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine in treatment-naïve patients with advanced pancreatic cancer met its primary endpoint of overall survival.

In the study, ABRAXANE in combination with gemcitabine demonstrated a statistically significant improvement in overall survival compared to patients receiving gemcitabine alone.

Also Friday:

Arno Therapeutics, Inc. (OTCBB: ARNI)
today reported progress in its clinical biomarker program to develop a companion diagnostic with onapristone in the treatment of breast and other cancers.

Array BioPharma Inc. (NasdaqGM: ARRY)
announced today the pricing of an underwritten public offering of 18,000,000 primary shares of its common stock at a public offering price of $3.65 per share.

BioMed Realty Trust, Inc. (NYSE: BMR)
will audio webcast the company's presentation at its Investor Day 2012 to be held on Monday, November 12, 2012 at the Marriott Marquis in San Diego.

Celsion Corporation (NASDAQ: CLSN)
, a leading oncology drug development company, today announced that it projects that a minimum of 380 events of progression have been realized in the Company's pivotal, Phase III HEAT Study, a multinational, double-blind, placebo-controlled, pivotal study of ThermoDox® in combination with radiofrequency ablation (RFA) for the treatment of hepatocellular carcinoma (HCC), also known as primary liver cancer.

Covidien plc (NYSE: COV)
today reported results for the fourth quarter of fiscal 2012 (July - September 2012).

Cyanotech Corporation (Nasdaq Capital Market: CYAN)
, a world leader in microalgae-based, high-value nutrition and health products, today announced financial results for the second quarter and first six months of fiscal year 2013, ended September 30, 2012.

CytRx Corporation (NASDAQ: CYTR)
, a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three months and nine months ended September 30, 2012.

Durata Therapeutics, Inc. (NASDAQ: DRTX)
today announced financial and corporate results for the quarter ended September 30, 2012.

Escalon® Medical Corp. (Nasdaq: ESMC)
today announced the partnering of its Sonomed Escalon™ group with Modernizing Medicine, Inc. to provide cloud-based end-to-end electronic medical records (EMR) and image management solutions for ophthalmic practices.

GenSpera, Inc. (OTCBB:GNSZ)
announced that interim data from its ongoing Phase I trial of G-202 in patients with advanced solid tumor cancers were presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland.

GenVec, Inc. (NASDAQ: GNVC)
announced financial results for the three months and nine months ended September 30, 2012.

Hansen Medical, Inc. (NASDAQ: HNSN)
, a global leader in intravascular robotics, today announced that President and CEO, Bruce Barclay, is scheduled to present at the 9th Annual Lazard Capital Markets Healthcare Conference.

Helix BioMedix, Inc. (OTCQB: HXBM)
, a developer of bioactive peptides, today announced financial results for the third quarter ended September 30, 2012.

HPIL Holding (the "Company") (OTCQB: HPIL)
is pleased to announce that, through its wholly owned subsidiary HPIL Art&Culture Inc. in association with Social Art World, it is participating in a conference on November 9, 2012, attended by M. Christian Parisot, President of the Modigliani Institute, Archives Legal Paris - Rome.

mPhase Technologies, Inc. (OTCBB: XDSL)
said today that it is developing plans to move the mPower Jump "Wherever You Go You're in Charge" a new class of jump starters for automobiles into low rate initial production (LRIP).

Omeros Corporation (NASDAQ: OMER)
today is addressing misleading statements in a press release issued yesterday by Davis Wright Tremaine, the law firm representing Richard J. Klein, Omeros' former chief financial officer with whom Omeros recently settled a lawsuit regarding his employment with Omeros.

Omeros Corporation (NASDAQ: OMER)
, a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its financial results for the third quarter of 2012.

Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY) today announced three poster presentations covering expanded results from: a Phase II clinical trial using intravenous administration of REOLYSIN in combination with paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) with Kras or EGFR-activated tumours (REO 016), a Phase II clinical trial using intravenous administration of REOLYSINin combination with gemcitabine (Gemzar®) in patients with advanced pancreatic cancer (REO 017), as well as preclinical research in Ras-activated pancreatic cancer.

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI)
announced today that Scott Cormack, President and Chief Executive Officer, will provide a corporate presentation at the Lazard Capital Markets Healthcare Conference on Wednesday, November 14, 2012 at 10:00 a.m. ET at the Pierre Hotel in New York City.

Palatin Technologies, Inc. (NYSE MKT: PTN)
will announce its first quarter, fiscal year 2013 financial results on Wednesday, November 14, 2012 before the open of the U.S. financial markets.

Rainbow BioSciences, the biotech subsidiary of Rainbow Coral Corp. (OTCBB: RBCC), and Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new disease-modifying treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury, have finalized the framework of their proposed joint venture (JV) and expect to execute material definitive agreements within 30 days, subject to closing documents.

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP)
today announced that educational activities and numerous presentations describing the investigation of XIFAXAN® 550mg/rifaximin will occur during The 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). AASLD 2012, or The Liver Meeting®, is being held in Boston, MA, November 9-13, 2012.

and Genzyme, a Sanofi Company, today congratulated John Zawacki, MD, of UMass Memorial Medical Center in Worcester, Massachusetts, the recipient of the 2012 Schwartz Center Compassionate Caregiver Award, for his display of extraordinary compassion in caring for patients and families.

Seattle Genetics, Inc. (NASDAQ:SGEN)
announced today that management will present at the upcoming Credit Suisse 2012 Healthcare Conference in Phoenix, Arizona.

Synta Pharmaceuticals Corp. (NASDAQ: SNTA)
today announced that the Company will present at the Lazard Capital Markets 9th Annual Healthcare Conference on Wednesday, November 14 at 10:30 a.m. (EST) in New York.

University General Health System, Inc. (OTCQB: UGHS)
, a diversified, integrated multi-specialty health delivery system, today announced that it will release its third quarter earnings on Wednesday, November 14, 2012, and will then host an investor conference call at 11:15 a.m. Eastern Time on Thursday, November 15, 2012, to discuss its operating results for the third quarter and first nine months of 2012, along with other topics of interest.

Verastem, Inc., (NASDAQ: VSTM)
a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, reported new data from its focal adhesion kinase (FAK) inhibition program and commented on encouraging clinical data on FAK inhibition presented at the 2012 EORTC Symposium on Molecular Targets and Cancer Therapeutics being held in Dublin, Ireland.

YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM)
, a drug development company advancing hematology and cancer related products, today reported operational and financial results for the first quarter of fiscal 2013, ended September 30, 2012.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus